|Mr. William J. Welch M.B.A.||Chief Exec. Officer, Principal Financial Officer and Director||435.49k||N/A||55|
|Dr. Mark Erlander Ph.D.||Chief Scientific Officer||608.4k||N/A||57|
|Dr. Karsten Schmidt Ph.D.||Chief Technology Officer||N/A||N/A||55|
|Ms. Elizabeth Anderson CPA||VP of Fin. and Admin.||N/A||N/A||N/A|
|Ms. Vicki Kelemen||Sr. Director of Communications||N/A||N/A||N/A|
Trovagene, Inc., a molecular diagnostic company, focuses on the development and commercialization of proprietary molecular genetic detection technology for use in pharmaceutical development, clinical research, and medical testing in various clinical disciplines in the United States. The company intends to enhance the treatment outcomes for cancer patients through its proprietary technology to detect and quantitatively monitor circulating tumor DNA (ctDNA) using urine or blood samples. It offers Precision Cancer Monitoring (PCM) platform, which provides cancer monitoring by tracking and quantifying levels of ctDNA from either urine or blood samples, as well as intends to offer clinical information beyond the current standard of care. The company also provides assays for the BRAF, KRAS, and epidermal growth factor receptor oncogenes; and engages in developing mutation coverage for other cancers, such as lung and colorectal cancers, as well as targeting clinically validated resistance mutations for gene rearrangements, including ALK, RET, and ROS. In addition, it offers laboratory developed tests for pharmaceutical companies and third party laboratories. The company has a license agreement with Nerviano Medical Sciences to develop and commercialize therapeutic candidate PCM-075. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene, Inc. in January 2010. Trovagene, Inc. was founded in 1999 and is headquartered in San Diego, California.
TrovaGene, Inc.’s ISS Governance QualityScore as of June 2, 2017 is 6. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 2; Compensation: 10.